Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.

Abstract excerpt

Targeting BTK has profoundly changed the face of CLL treatment over the past decade. Iterative advances in the cat and mouse game of resistance and redesign have moved BTK inhibitors from covalent to non-covalent and now targeted protein degraders. However, contrary to the presumption that protein degraders may be impervious to mutations in BTK, we now present clinical evidence that a mutation in the kinase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Agammaglobulinaemia Tyrosine Kinase
• Share to Aged
• Share to Drug Resistance, Neoplasm